Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[PDE5 inhibitors in treatment of benign prostatic syndrome].
Sandner P, Tinel H, Stelte-Ludwig B, Huetter J, Neuser D, Bischoff E, Ulbrich E. Sandner P, et al. Urologe A. 2007 Sep;46(9):1189-92. doi: 10.1007/s00120-007-1478-3. Urologe A. 2007. PMID: 17609921 Clinical Trial. German. No abstract available.
PDE5 inhibitors beyond erectile dysfunction.
Sandner P, Hütter J, Tinel H, Ziegelbauer K, Bischoff E. Sandner P, et al. Int J Impot Res. 2007 Nov-Dec;19(6):533-43. doi: 10.1038/sj.ijir.3901577. Epub 2007 Jul 12. Int J Impot Res. 2007. PMID: 17625575 Review.
Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
Füllhase C, Hennenberg M, Sandner P, Strittmatter F, Niedworok C, Bauer RM, Gratzke C, Soler R, Stief C, Andersson KE. Füllhase C, et al. Among authors: sandner p. Neurourol Urodyn. 2015 Nov;34(8):787-93. doi: 10.1002/nau.22665. Epub 2014 Sep 17. Neurourol Urodyn. 2015. PMID: 25230878
Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
Uvin P, Albersen M, Bollen I, Falter M, Weyne E, Linsen L, Tinel H, Sandner P, Bivalacqua TJ, De Ridder DJ, Van der Aa F, Brône B, Van Renterghem K. Uvin P, et al. Among authors: sandner p. BJU Int. 2017 Feb;119(2):325-332. doi: 10.1111/bju.13691. Epub 2016 Nov 21. BJU Int. 2017. PMID: 27763717
129 results